Start Licensing, Inc. Reaffirms Control of Key Cloning Patents

Firm responds to South Korean company's recent actions
AUSTIN, Texas--(Business Wire)--
Today Start Licensing, Inc. (Start) reaffirmed that it controls
key patents in Korea and elsewhere that cover animal cloning
technology, including the technology used to clone dogs. RNL Bio Ltd
(RNL) previously announced on February 12, 2008 that it was launching
a dog cloning service and had signed its first client. More recently
it has been reported that RNL is offering cloned cancer-sniffing dogs
for commercial sale. RNL is not licensed under Start's patents to
engage in these commercial activities.

The patents Start controls include Korean Patent Nos. 10-0533476,
10-0533477, 10-0743006, and 10-0793220 as well as numerous foreign
counterparts in the U.S., Europe, Japan and elsewhere. These patents
are part of a portfolio of patents and patent applications directed to
foundational somatic cell nuclear transfer (SCNT) cloning technology.
Start recently granted a sole, worldwide license under these patents
to BioArts International Ltd. for cloning dogs and cats.

"Start will pursue available legal remedies as necessary to
protect and preserve its patent rights," said Jonathan Thatcher,
President of Start Licensing, "including the remedy of blocking
importation of products produced under the patented methods into
jurisdictions where such rights are available."

About Start Licensing

Start is a joint venture of Geron Corporation (Nasdaq: GERN) and
Exeter Life Sciences, Inc. Start manages and licenses a broad
portfolio of intellectual property rights related to animal
reproductive technologies, including foundational nuclear transfer
cloning technology developed at the Roslin Institute for the cloning
of Dolly the sheep. Start's licensees are on the cutting edge of
research and product development in food production, medical
applications and many other fields.

Start Licensing, Inc.
Ben Carlson, 202-466-9633
ben@turnerstrategies.com

Copyright Business Wire 2008